Novo Nordisk, Ozempic
Novo Nordisk’s Ozempic Shortage Is Worsening. That’s Good for Eli Lilly Stock.
While Novo is struggling to keep up with demand for its obesity drugs, U.S. rival Eli Lilly sees supply restraints easing.
Novo Nordisk's Ozempic shortage expected to continue into Q4
Novo Nordisk said the shortage of lower strengths of its diabetes drug Ozempic has deteriorated, with intermittent shortages for all strengths expected into the final quarter of 2024 due to increased demand and along with capacity constraints at some of its manufacturing sites.
Novo’s Ozempic to Remain in Shortage Into Q4 as Supply Woes Continue
Novo’s continuing supply problems for semaglutide comes as the pharma tries to expand the drug’s indication, opening it up to more patients—and potentially to heavier production pressures.
This New Finding About Ozempic and Wegovy Could Hurt Novo Nordisk's Stock
Novo Nordisk 's ( NVO 1.19%) GLP-1 medicines, Ozempic and Wegovy, are bestsellers and household names. Whereas Ozempic is indicated for type 2 diabetes, Wegovy is prescribed for weight loss in the context of obesity. But, if some new information holds true, the company could soon see its presence in both of those markets take a hit.
In Europe, shortages of Novo Nordisk's Ozempic to persist into Q4: letter
Novo Nordisk responded to a growing shortage of popular Ozempic with a plan to cut down on production of its older diabetes med Victoza to make room for more Ozempic. | The company and the European Medicines Agency warned European healthcare providers to continue limiting new patient prescriptions until the shortages let up.
Novo highlights heart benefits of weight loss drug with new analysis
Novo Nordisk (NVO) posts new data to show the potential of its weight loss therapy semaglutide in reducing heart failure risk. Read more here.
Novo Nordisk Warns Of Weight Loss Drug Shortage
Novo Nordisk (NVO) is warning about a growing shortage of its popular weight loss drug Ozempic. The Danish pharmaceutical company has issued a statement saying that the current shortage of Ozempic, which is also used to treat diabetes,
Kepler Capital Remains a Hold on Novo Nordisk (0QIU)
Kepler Capital analyst David Evans maintained a Hold rating on Novo Nordisk (0QIU – Research Report) on September 2 and set a price ...
Novo to Supply Half of Danish Growth in 2024, Danske Says
Novo Nordisk A/S is likely to contribute about half of Denmark’s economic expansion this year, helping the nation to ...
The Motley Fool3d
These 3 Factors Could Make Eli Lilly Stock a Better Buy Than Novo Nordisk Right Now
Eli Lilly and Novo Nordisk compete in a handful of different markets. Novo Nordisk is scaling up its output and ...
STAT4d
New Wegovy analysis could boost Novo Nordisk’s bid to expand drug’s label in heart failure
Novo Nordisk’s Wegovy cut the risk of severe complications in patients with a common form of heart failure, according to a ...
FiercePharma4d
Novo rekindles heart failure hopes for semaglutide with new pooled analysis
After a regulatory hiccup earlier this month, Novo Nordisk’s heart failure ambitions for its obesity star Wegovy ...
ENDPOINTS NEWS14h
No­vo Nordisk con­tin­ues to grap­ple with patchy GLP-1 drug sup­ply in Eu­rope
All doses of Novo Nordisk’s Ozempic are expected to face “intermittent shortages” in Europe during the fourth quarter of the ...
Novo, Amgen, Other Pharma Stocks Have Clinical Trials That Could Send Them Soaring
Upcoming results from a bunch of clinical trials could extend the rally stocks have already been enjoying the past few years.
Trade Arabia1d
MoHAP signs agreement with Novo Nordisk Pharma Gulf
UAE’s Ministry of Health and Prevention (MoHAP) has teamed up with Novo Nordisk Pharma Gulf, a major player in global healthcare, to create a national scientific guide to tackle obesity and manage ...